VEA
SLNO

Virtus ETF Advisers’s Soleno Therapeutics SLNO Stock Holding History

Virtus ETF Advisers’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,536
Closed -$69K – 744
2024
Q4 		$69K Sell
1,536
-514
-25% -$26.6K 0.03% 383
2024
Q3 		$104K Buy
2,050
+39
+2% +$1.87K 0.05% 373
2024
Q2 		$82K Sell
2,011
-316
-14% -$13.4K 0.04% 397
2024
Q1 		$99.6K Sell
2,327
-163
-7% -$7.37K 0.05% 366
2023
Q4 		$100K Buy
+2,490
New +$70.8K 0.06% 359

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtus ETF Advisers's SLNO Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Soleno Therapeutics (SLNO) in Q1 2025, closing a stake of 1,536 shares — an estimated $69K sold.

Virtus ETF Advisers first reported a position in SLNO in Q4 2023 and held it in 5 quarters. The position peaked at $104K in Q3 2024. 217 funds tracked by Wall St. Rank hold SLNO as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Soleno Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,536 Soleno Therapeutics shares in Q1 2025, an estimated $69K.
  • Virtus ETF Advisers first reported a position in Soleno Therapeutics in Q4 2023 and held it in 5 quarters.
  • Virtus ETF Advisers's Soleno Therapeutics position peaked at $104K in Q3 2024.
  • 217 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.